Uterovesical tourniquet for conservative management of placenta accreta spectrum: a prospective cohort study in a low-resource setting

子宫膀胱止血带用于胎盘植入谱系疾病的保守治疗:一项在资源匮乏地区开展的前瞻性队列研究

阅读:1

Abstract

BACKGROUND: Placenta accreta spectrum (PAS) is a condition affecting the placental detachment during labour and could be associated with life-threatening haemorrhage. We evaluated a novel uterovesical tourniquet technique to reduce blood loss during uterine sparing surgery. METHODS: This is a prospective cohort study that was conducted between 01/10/2023 and 01/04/2024, at Cairo University Hospital. Pregnant women with confirmed intra operative diagnosis of PAS were recruited to this study. The study included the application of a tourniquet around the lower part of the uterus and bladder before the delivery of the fetus to control blood loss during the operation. The primary outcomes were the operative procedure performed (Uterine sparing surgery Vs Caesarean Hysterectomy) and the measurement of the intraoperative blood loss. RESULTS: Twelve patients were included in this study. The average gestational age at deliver was 35.17 weeks ± 0.72. The uterine sparing surgery was successful in 11 out of the 12 patients (91.7%). The mean intraoperative blood loss was 950 mL ± 233.55 and the average operative time was 84.58 min ± 41.64. The mean number of packed RBCs units' transfused was 1.58 units ± 1.38. One bladder injury occurred. CONCLUSION: The uterovesical tourniquet may reduce haemorrhage in PAS, offering a feasible option for resource-limited settings. TRIAL REGISTRATION: This trial has been registered on clinicaltrials.gov with the identifier NCT06185894.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。